AP NEWS

Crown Bioscience to Showcase Scientific Expertise at the EORTC-NCI-AACR

November 6, 2018

New model data released including Prostate Cancer PDX and humanized target models for the evaluation of combination human checkpoint inhibitors

SAN DIEGO, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, will showcase scientific expertise with ten scientific posters at Booth A9 at the 30th EORTC-NCI-AACR Symposium on November 13-16 in Dublin.

The meeting focuses on the discussion of the latest development in targets and therapeutics with dedicated sessions to review novel experimental models and progress in immunotherapy.

At this meeting, CrownBio will present data on its most recent scientific advancements in model development and immunotherapy research. The Company will report on the establishment and characterization of a panel of patient-derived xenografts (PDX) of prostate cancer, a tumor indication that has historically witnessed a shortage of preclinical models.

Further enhancements to CrownBio’s immuno-oncology platforms will be presented with innovative models for the evaluation of combination strategies of human immune checkpoint inhibitors, and PBMC humanized models for bispecific antibody testing. Additionally, data will be presented on CrownBio’s unique collection of immunocompetent murine homograft tumors driven by human disease pathway and well-characterized syngeneic models for the evaluation of surrogate or cross-reactive agents.

The authors of ten CrownBio scientific posters will present their data from 10:00 a.m. to 5:30 p.m. November 14 (poster 226), and from 10:00 a.m. to 5:30 p.m. November 15 (posters 240, 241, 250, 304, 305, 312, 313, 327, 329).

“Our seminal work using diverse mouse homografts with engineered human disease pathways and humanized models for immuno-oncology, combined with the in-depth genomic characterization of our PDX tumors demonstrates our deep commitment to investing in innovative R&D programs that advance immunotherapy and prostate cancer research,” said Henry Li, Ph.D., Senior VP of Research and Innovation at CrownBio.

To discuss current and upcoming oncology research projects with CrownBio’s experts and book a meeting visit https://www.crownbio.com/ena18-posters

About Crown Bioscience Inc. CrownBio is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, CrownBio enables clients to deliver superior clinical candidates. For more information about CrownBio visit: https://www.crownbio.com

Media Enquiries:Jody BarbeauCrown Bioscience Inc. marketing@crownbio.com

AP RADIO
Update hourly